This supports our preclinical observations that ER signaling, and ER-mediated breast cancer cell growth, is maintained in a post-CDK4/6i setting and warrants the evaluation of elacestrant in patients after disease progression on a CDK4/6 inhibitor. Here, CDK4 is linked to breast carcinoma.